Skip to main content

Table 1 Baseline demographics and baseline characteristics of the study groups

From: Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study

  Glimepiride Vildagliptin
n 22 22
Male / female 13 / 9 15 / 7
Age (years) 60 ± 7 57 ± 9
Duration of diabetes (years) 6.1 ± 4.4 8.4 ± 9.0 $
HbA1c (%) 7.3 ± 0.6 7.4 ± 0.7
BMI (kg/m2) 33.3 ± 6.7 34.6 ± 5.9
  1. mean ± SD; $ = p < 0.05 in between both groups.